Exopolysaccharide-peptide complex from oyster mushroom (Pleurotus ostreatus) protects against hepatotoxicity in rats

Journal article


Abdel-Monem, NM, El-Saadani, MA, Daba, AS, Saleh, SR and Aleem, E (2020). Exopolysaccharide-peptide complex from oyster mushroom (Pleurotus ostreatus) protects against hepatotoxicity in rats. Biochemistry and Biophysics Reports. 24, pp. 100852-100852. https://doi.org/10.1016/j.bbrep.2020.100852
AuthorsAbdel-Monem, NM, El-Saadani, MA, Daba, AS, Saleh, SR and Aleem, E
Abstract

© 2020 Liver damage involves oxidative stress and a progression from chronic hepatitis to hepatocellular carcinoma (HCC). The increased incidence of liver disease in Egypt and other countries in the last decade, coupled with poor prognosis, justify the critical need to introduce alternative chemopreventive agents that may protect against liver damage. The aim of this study was to evaluate the efficacy of exopolysaccharide-peptide (PSP) complex extracted from Pleurotus ostreatus as a hepatoprotective agent against diethylnitrosamine (DEN)/carbon tetrachloride (CCL4)-induced hepatocellular damage in rats. The levels of liver injury markers (ALT, AST and ALP) were substantially increased following DEN/CCl4 treatment. DEN/CCl4 - induced oxidative stress was confirmed by elevated levels of lipid peroxidation and decreased levels of superoxide dismutase, glutathione-S-transferase, and reduced glutathione. PSP reversed these alterations in the liver and serum, and provided protection evidenced by reversal of histopathological changes in the liver. The present study demonstrated that PSP extract from P. ostreatus exhibited hepatoprotective and antioxidant effects against DEN/CCl4-induced hepatocellular damage in rats. Given the high prevalence of HCV-related liver damage in Egypt, our results suggest further clinical evaluation of P. ostreatus extracts and their potential hepatoprotective effects in patients with liver disease.

Year2020
JournalBiochemistry and Biophysics Reports
Journal citation24, pp. 100852-100852
PublisherElsevier BV
ISSN2405-5808
Digital Object Identifier (DOI)https://doi.org/10.1016/j.bbrep.2020.100852
Publication dates
Print01 Dec 2020
Publication process dates
Accepted12 Nov 2020
Deposited07 Dec 2020
Publisher's version
License
File Access Level
Open
Permalink -

https://openresearch.lsbu.ac.uk/item/8v8vy

Download files


Publisher's version
1-s2.0-S240558082030162X-main.pdf
License: CC BY-NC-ND 4.0
File access level: Open

  • 115
    total views
  • 82
    total downloads
  • 0
    views this month
  • 0
    downloads this month

Export as

Related outputs

Identifying lifestyle factors associated to co-morbidity of obesity and psychiatric disorders, a pilot study
Gaskell, C., Sarada, P., Aleem, E. and Bendriss, D.G. (2023). Identifying lifestyle factors associated to co-morbidity of obesity and psychiatric disorders, a pilot study. Frontiers in Public Health. 11, p. 1132994. https://doi.org/10.3389/fpubh.2023.1132994
Nanoparticle mediated cancer cell therapy: Basic science to clinical applications
Verma, J., Warsame, C., Seenivasagam, R.K., Kumar, N., Abdel Aleem, E. and Goel, S. (2023). Nanoparticle mediated cancer cell therapy: Basic science to clinical applications. Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-023-10086-2
Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis
Azorsa, DO, Lee, DW, Wai, DH, Bista, R, Patel, AR, Aleem, E, Henry, MM and Arceci, RJ (2018). Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis. Pediatric Blood and Cancer. 65 (9), pp. e27237-e27237. https://doi.org/10.1002/pbc.27237
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
Bista, R, Lee, DW, Pepper, OB, Azorsa, DO, Arceci, RJ and Aleem, E (2017). Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells. Journal of Experimental & Clinical Cancer Research. 36 (22). https://doi.org/10.1186/s13046-017-0493-5
Nuclear insulin-like growth factor 1 receptor phosphorylates proliferating cell nuclear antigen and rescues stalled replication forks after DNA damage
Waraky, A, Lin, Y, Warsito, D, Haglund, F, Aleem, E and Larsson, O (2017). Nuclear insulin-like growth factor 1 receptor phosphorylates proliferating cell nuclear antigen and rescues stalled replication forks after DNA damage. Journal of Biological Chemistry. 292 (44), pp. 18227-18239. https://doi.org/10.1074/jbc.M117.781492
Downregulation of IGF-1 receptor occurs after hepatic linage commitment during hepatocyte differentiation from human embryonic stem cells
Waraky, A, Aleem, E and Larsson, O (2016). Downregulation of IGF-1 receptor occurs after hepatic linage commitment during hepatocyte differentiation from human embryonic stem cells. Biochemical and Biophysical Research Communications. 478 (4), pp. 1575-1581. https://doi.org/10.1016/j.bbrc.2016.08.157
Targeting cell cycle regulators in hematologic malignancies
Aleem, E. and Arceci, R.J. (2015). Targeting cell cycle regulators in hematologic malignancies. Frontiers in Cell and Developmental Biology. 3 (APR), pp. 16-. https://doi.org/10.3389/fcell.2015.00016
Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism
Waraky, A., Akopyan, K., Parrow, V., Strömberg, T., Axelson, M., Abrahmsén, L., Lindqvist, A., Larsson, O. and Aleem, E. (2014). Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism. Oncotarget. 5 (18), pp. 8379-8392. https://doi.org/10.18632/oncotarget.2292